KIT and leukemia: According to our findings (also confirmed here), we can deduce that Kit-M might trigger, with higher efficacy, improved/mediated antileukemic reactions compared to Kit I. Moreover, we show that the achieved antileukemic activities (achieved using patients’ samples at first diagnosis) are independent of patients’ sex, cytogenetic risk and blast counts (patients with leukemia in remission might profit from these Kit-mediated effects; (residual) blasts are converted to DCleu and trigger the immune system specifically against blasts).